13 Results for "

overweight

" in MedChemExpress (MCE) Product Catalog:
Products (13)

13 Results for "overweight" in MCE Product Catalog:

1
1 Cited Publications
Cat. No.: HY-P3463
CAS No.: 123475-27-4
Synonyms: GLP-1 (human)
Target:  

GCGR

Beinaglutide is a human GLP-1 polypeptide that shares almost 100% homology with human GLP-1 (7–36). Beinaglutide displays does-dependent effects in glycemic control, inhibiting food intake and gastric empty and promoting weight loss. Beinaglutide has the potential for the research of overweight/obesity and nonalcoholic steatohepatitis (NASH) .
loading...
    loading...
Cat. No.: HY-P11274A
Synonyms: Amycretin sodium; NN 9487 sodium
Research Areas:  

Metabolic Disease

Zenagamtide (Amycretin; NN 9487) sodium is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide sodium is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide sodium improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide sodium may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
loading...
    loading...
Cat. No.: HY-P11274
CAS No.: 3005889-81-3
Synonyms: Amycretin; NN 9487
Research Areas:  

Metabolic Disease

Zenagamtide (Amycretin; NN 9487) is an orally active, blood-brain barrier permeable triple agonist that targets GLP-1, amylin (Amylin Receptor) and calcitonin receptor (Calcitonin Receptor). Zenagamtide is a single peptide consisting of 68 amino acids that can target brain regions regulating food intake, significantly suppress appetite and reduce energy intake. Therefore, Zenagamtide improves body weight, waist circumference, glycated hemoglobin and lipid profile, and also alleviates the histological features of metabolic dysfunction-associated steatotic liver disease (MASLD) and enhances insulin sensitivity. Zenagamtide may cause transient increases in heart rate and fluctuations in serum calcium levels, but it is an important compound for the study of overweight, obesity, insulin resistance and related metabolic diseases .
loading...
    loading...
Cat. No.: HY-114557
CAS No.: 1041-01-6
Purity:  99.38%
Synonyms: 3,5-Diiodo-L-thyronine
NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .
loading...
    loading...
Cat. No.: HY-164236
CAS No.: 119242-44-3
Target:  

Endogenous Metabolite

Research Areas:  

Metabolic Disease

C22 Glucosylceramide (d18:1/22:0) is a bioactive sphingolipid composed of a d18:1 sphingoid base and a 22:0 fatty acid chain. C22 Glucosylceramide (d18:1/22:0) specifically exists in Doxorubicin (HY-15142A)-sensitive cancer cells, and its circulating concentration is positively correlated with the incidence of cardiovascular events. C22 Glucosylceramide (d18:1/22:0) has been widely used in research related to cardiovascular diseases, hypercholesterolemia, metabolic syndrome, breast adenocarcinoma and other fields .
loading...
    loading...
Cat. No.: HY-P11235
CAS No.: 3028974-74-2
Synonyms: PF-08653944; MET-097
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Berobenatide (PF-08653944; MET-097) is a GLP-1R agonist that exerts functional regulation of GLP-1R biased toward the Gs protein signaling pathway. Berobenatide induces weight loss in diet-induced obese mice. Berobenatide can be used in obesity-related research .
loading...
    loading...
Cat. No.: HY-P10965
CAS No.: 3013543-64-8
Synonyms: ZT002
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Zovaglutide (ZT002) is a long-acting, selective GLP-1 receptor agonist. Zovaglutide enhances albumin binding capacity via dual fatty acid chain modification. Zovaglutide exerts metabolic effects through central and peripheral GLP-1 pathways, thereby promoting satiety, reducing caloric intake and enhancing glucose-dependent insulin secretion, with no activity against GIP or glucagon receptors. Zovaglutide can be used in research on type 2 diabetes or obesity .
loading...
    loading...
Cat. No.: HY-114557R
CAS No.: 1041-01-6
Synonyms: 3,5-Diiodo-L-thyronine (Standard)
NSC 90469 (Standard) is the analytical standard of NSC 90469. This product is intended for research and analytical applications. NSC 90469 (3,5-Diiodo-L-thyronine) is an orally active thyroid hormone derivative. NSC 90469 inhibits JNK phosphorylation and NF-κB acetylation, blocks SIRT1 protein expression, induces elevated PGC-1α levels, and stimulates COX activity. NSC 90469 enhances UCP1-mediated thermogenesis, increases hepatic Dio1 activity, inhibits TSH levels and hypothalamic-pituitary-thyroid axis function, enhances lipid metabolism, and regulates energy metabolism via the mitochondrial pathway. NSC 90469 prevents blood glucose reduction, reduces urinary albumin excretion, inhibits renal matrix expansion, decreases TGF-β1 expression, and reduces renal fibronectin and type Ⅳ collagen deposition. NSC 90469 also increases energy expenditure and prevents diet-induced overweight. NSC 90469 can be used in studies related to diabetic nephropathy, hypothyroidism, non-alcoholic fatty liver disease, and diet-induced obesity .
loading...
    loading...
Cat. No.: HY-N19253
CAS No.: 1911579-97-9
9,12-Hexadecadienoylcarnitine is an acylcarnitine. The level of 9,12-Hexadecadienoylcarnitine increases during mild weight loss induced by a 12-week low-calorie diet. The serum level of 9,12-Hexadecadienoylcarnitine is upregulated in models of reduced intrinsic capacity. 9,12-Hexadecadienoylcarnitine can be used in studies related to overweight and reduced intrinsic capacity .
loading...
    loading...
Cat. No.: HY-P11235A
Synonyms: PF-08653944 acetate; MET-097 acetate
Target:  

GLP Receptor

Research Areas:  

Metabolic Disease

Berobenatide acetate (PF-08653944 acetate; MET-097 acetate) is a GLP-1R agonist that exerts functional regulation of GLP-1R biased toward the Gs protein signaling pathway. Berobenatide acetate induces weight loss in diet-induced obese mice. Berobenatide acetate can be used in obesity-related research .
loading...
    loading...
Cat. No.: HY-107317
CAS No.: 1449-61-2
Synonyms: 7-Keto-DHEA acetate; NSC 134911; 7-Oxodehydroepiandrosterone 3-acetate
7-Keto Naturalean (7-Keto-DHEA acetate) is a DHEA (HY-14650) analog and weight-loss agent. 7-Keto Naturalean not only exerts anti-aging effects, enhances immunity, improves brain function, boosts memory, prevents Alzheimer's disease, and stimulates the metabolism of hepatic active enzymes, especially thermogenic enzymes, but also functions to reduce fat mass and increase the density and vitality of bones and muscles .
loading...
    loading...
Cat. No.: HY-179728
Research Areas:  

Metabolic Disease

Amylin agonist 1 is an agonist of amylin receptor 3 (AMY3R), with an EC50 of 6.17 nM for stimulating cellular cAMP production. Amylin agonist 1 is also an agonist of calcitonin receptor (CTR), with an EC50 of 8.58 nM. Amylin agonist 1 can be used for the research of type 2 diabetes and obesity .
loading...
    loading...
Cat. No.: HY-184966
CAS No.: 3059496-70-4
GIPR antagonist 4 is an orally active GIPR antagonist with an IC50 of 4.1 nM. GIPR antagonist 4 exerts its antagonistic effect by competitively binding to GIPR and blocking the increase in Gαs-mediated cAMP production induced by GIP agonists. The combination of GIPR antagonist 4 and Liraglutide (HY-P0014) can enhance the weight loss effect of the single drug. GIPR antagonist 4 can be used for research related to obesity and metabolic diseases .
loading...
    loading...
  • 1